Get the Stockscreener App
1.52
1.30%
-0.02
Theratechnologies Inc stock is traded at $1.52, with a volume of 62,362.
It is down -1.30% in the last 24 hours and down -6.75% over the past month.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
See More
Previous Close:
$1.54
Open:
$1.56
24h Volume:
62,362
Relative Volume:
0.51
Market Cap:
$69.89M
Revenue:
$84.32M
Net Income/Loss:
$-3.16M
P/E Ratio:
-30.40
EPS:
-0.05
Net Cash Flow:
$-4.50M
1W Performance:
-1.94%
1M Performance:
-6.75%
6M Performance:
+12.59%
1Y Performance:
+26.67%
1-Day Range:
$1.50
$1.5899
1-Week Range:
$1.45
$1.59
52-Week Range:
$1.08
$2.18
Theratechnologies Inc Stock (THTX) Company Profile
Compare THTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THTX
Theratechnologies Inc
|
1.52 | 69.89M | 84.32M | -3.16M | -4.50M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Theratechnologies Inc Stock (THTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Theratechnologies Inc Stock (THTX) Latest News
Theratechnologies Inc. - Baystreet.ca
Stocks In Play: Theratechnologies Inc. - Barchart
Theratechnologies CROI Presentation Highlights Limitations - GlobeNewswire
Theratechnologies Reports Encouraging Results From PROMISE-US Trial Of Ibalizumab - Nasdaq
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of ... - The Bakersfield Californian
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI - GlobeNewswire
Groundbreaking Research Shows BMI Misses Critical Heart Risks in 43% of HIV Patients - StockTitan
Theratechnologies Inc. to Host Earnings Call - ACCESS Newswire
Theratechnologies, Inc. to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for THTX FY2027 Earnings - Defense World
FY2025 EPS Estimates for TSE:TH Reduced by Leede Financial - MarketBeat
Theratechnologies (NASDAQ:THTX) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Leede Financial Brokers Reduce Earnings Estimates for TSE:TH - Defense World
Theratechnologies (NASDAQ:THTX) Issues Earnings Results - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 212.7% in February - Defense World
Research Analysts Set Expectations for THTX FY2025 Earnings - Defense World
Theratechnologies’ Earnings Call: Growth Amid Challenges - TipRanks
What is Leede Financial's Estimate for THTX FY2025 Earnings? - MarketBeat
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... - Yahoo Finance
Theratechnologies Reports Strong Fiscal 2024 Performance - TipRanks
Theratechnologies reports Q4 revenue $25M vs $23.45M last year - TipRanks
Theratechnologies: Fiscal Q4 Earnings Snapshot - mySA
Theratechnologies Inc reports results for the quarter ended November 30Earnings Summary - TradingView
Earnings call transcript: Theratechnologies Q4 2024 sees growth amid strategic shifts - Investing.com UK
Theratechnologies: Fiscal Q4 Earnings Snapshot -February 26, 2025 at 07:55 am EST - Marketscreener.com
Theratechnologies Achieves Record Financial Results and Secures Future Growth - TipRanks
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 - GlobeNewswire
From Losses to Record Profits: How Theratechnologies Turned Around Its Financials in 2024 - StockTitan
Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to K - GuruFocus.com
Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
Theratechnologies Resumes EGRIFTA SV® Distribution Following FDA Approval - TipRanks
Theratechnologies (THTX) Stock Price, News & Analysis - MarketBeat
Theratechnologies (THTX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Drops By 73.4% - MarketBeat
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025 - ADVFN
Theratechnologies (THTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide ... - Walla Walla Union-Bulletin
Q4 Earnings Preview: Theratechnologies CEO to Unveil Strategic Vision Alongside 2024 Financial Results - StockTitan
Theratechnologies Resumes EGRIFTA SV® Distribution Following FDA Clearance - TipRanks
Major HIV Treatment Back in Stock: FDA Greenlights EGRIFTA SV Distribution to US Pharmacies - StockTitan
Theratechnologies Resumes Distribution of EGRIFTA SV® - GlobeNewswire
Theratechnologies (TSE:TH) Trading Up 1.9%Here's Why - MarketBeat
Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World
Theratechnologies Inc Stock (THTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):